<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="28680">Cytarabine</z:chebi> (ara-C) is the first line agent with its excellent activity for <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Combination therapy of MFC (<z:chebi fb="0" ids="27504">mitomycin C</z:chebi>, 5-FU, ara-C) has been used for GI tract <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> with a synergistic effect on L-1210 mouse <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In the results of research on the administration, a high dose ara-C is an effective agent in the refractory cases to the standard dose ara-C and the combination with <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> is applied to a remission consolidation therapy </plain></SENT>
<SENT sid="3" pm="."><plain>A small dose ara-C is used against an atypical <z:hpo ids='HP_0001909'>leukemia</z:hpo> with its mechanism of induction of differenciation </plain></SENT>
<SENT sid="4" pm="."><plain>On the other hand, in the development of its derivertive compounds ancitabine or enocitabine (BH-AC) were induced to a treatment of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Especially BH-AC is the first choice agent for <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> combined with other agents </plain></SENT>
</text></document>